Regenerative Medicine Market to Reach $5.5 Billion by 2025: Regional Estimates & Trend Analysis, by Product and Therapeutic Category – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Regenerative
Medicine Market, 2014 – 2025”
report has been added to Research
and Markets’
offering.

The global regenerative medicine market size is expected to reach USD
5.59 billion by 2025, according to this new report. Increased prevalence
of neurodegenerative, orthopedic, and other aging-related disorders in
geriatric population coupled with rising global geriatric population is
anticipated to drive market growth.

Developments in biotechnology have enabled gaining in-depth knowledge
pertaining to cell division and differentiation as well as the
metabolism mechanism of various cells. This enriched knowledge, coupled
with emergence of novel streams of biotechnology such as gene therapy
and nanotechnology, further prospered use of cell-based technology in
therapeutic treatment.

Identification of ability of stem cells to develop into various
different cell lines further propelled the advancements in regenerative
medicine. Frequent media exposure due to regulatory as well as ethical
controversies around embryonic stem cells has increased awareness among
the masses. This encouraged researchers to explore and develop other
potential fields for similar applications, such as induced pluripotent
stem cells (iPSC).

Furthermore, the emergence of gene therapy techniques with potential to
rectify and restore effects of gene mutations in cells is under
development. Conditions caused due to Single Nucleotide Polymorphism
(SNP) as well as mutations that induce degenerative characteristics are
primarily targeted.

Companies Mentioned

  • Integra LifeSciences Corporation
  • Astellas Pharma Inc.
  • Ocata Therapeutics, Inc.
  • Corline Biomedical AB
  • Cook Biotech
  • Bayer BV
  • BlueRock Therapeutics
  • AstraZeneca
  • MedImmune
  • F. Hoffmann-La Roche Ltd
  • Pfizer Inc.
  • Merck & Co., Inc.
  • Sigma-Aldrich Co. LLC
  • Merck Millipore
  • Abbott
  • St. Jude Medical, Inc.
  • Vericel Corporation
  • Novartis AG
  • Alcon
  • GlaxoSmithKline plc.
  • (15+ Others)

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Regenerative Medicine Market Variables, Trends & Scope

4. Regenerative Medicine Market: Product Type Estimates & Trend Analysis

5. Regenerative Medicine Market: Therapeutic Category Estimates & Trend
Analysis

6. Regenerative Medicine Market: Regional Estimates & Trend Analysis, by
Product And Therapeutic Category

7. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/ljltv2/regenerative

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Biopharmaceuticals

Vaccine Delivery Devices Market 2014-2017 & 2025 By Devices (Syringes, Jet Injectors) & By Route of Administration (Intradermal Vaccination, Intramuscular Vaccination, Subcutaneous Vaccination) – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Vaccine
Delivery Devices Market Analysis By Devices (Syringes, Jet Injectors,
Other Devices), By Route of Administration (Intradermal Vaccination,
Intramuscular Vaccination, Subcutaneous Vaccination, Others), And
Segment Forecasts, 2014 – 2025”
report has been added to Research
and Markets’
offering.

The global vaccine delivery devices market is expected to reach USD 6.21
billion by 2025

The market is primarily driven by growing immunization programs,
financial support from government & nongovernment organizations,
increasing vaccination initiatives & campaigns, and rising prevalence of
infectious diseases globally. Growing research in the field of vaccines
and development of new products is also contributing to the growth of
the market.

Adoption of needle-free approach for administering these products is
gaining momentum due to growing awareness and demand to avoid pain &
injuries associated with the use of a needle stick. Data by the Centers
for Disease Control and Prevention states that an estimated 385,000
sharp injuries including needle stick injuries occur every year in
hospitals in the U.S. Advancing technologies in administering vaccines
and their increasing adoption is propelling market growth. Rising
interest of various key players, national institutions, and
organizations in novel delivery technologies is expected to further
contribute to market growth.

Various governments and international organizations are increasingly
investing in the development of vaccination programs. For instance, the
UK government also announced funding up to £1 million from its Global
Challenges Research Fund through Medical Research Council to investigate
the Zika virus and its transmission. Organizations such as GAVI
Alliance, Bill & Melinda Gates Foundation, Path, and WHO are actively
involved in the field of vaccines. Many governments are also undertaking
several immunization programs on priority.

Key Topics Covered:

1 Research Methodology

2. Executive Summary

3. Vaccine Delivery Devices Market Variables, Trends & Scope

4. Vaccine Delivery Devices Market: Devices Estimates & Trend Analysis

5. Vaccine Delivery Devices Market: Route of Administration Estimates &
Trend Analysis

6. Vaccine Delivery Devices Market: Regional Estimates & Trend Analysis
by Devices And Route of Administration

7. Competitive Landscape

– Becton Dickinson & Company

– BioJect Medical Technologies, Inc. (Inovio Pharmaceuticals, Inc.)

– Pharmajet, Inc

– Valeritas

– Vaxxas

– Gerresheimer AG

– Schott AG

– 3M

– Corium International, Inc

For more information about this report visit https://www.researchandmarkets.com/research/qkkrt6/vaccine_delivery

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Vaccines

Senseonics Holdings, Inc. Announces Pricing of Public Offering of Common Stock

GERMANTOWN, Md.–(BUSINESS WIRE)–Senseonics Holdings, Inc. (NYSE MKT: SENS), a medical technology company
focused on the development and commercialization of Eversense®, a
long-term, implantable continuous glucose monitoring (CGM) system for
people with diabetes, today announced the pricing of its previously
announced underwritten public offering. Senseonics is offering
11,637,500 shares of its common stock, par value $0.001 per share, at a
price to the public of $2.15 per share. In connection with the offering,
Senseonics has also granted the underwriter a 30-day option to purchase
up to an additional 1,745,625 shares of common stock offered in the
public offering to cover over-allotments, if any. Senseonics intends to
use the net proceeds from the offering primarily to begin
commercialization of Eversense in the United States, if approved, to
fund continued research and development of future configurations of
Eversense, and for working capital and general corporate purposes. The
offering is expected to close on August 23, 2017, subject to the
satisfaction or waiver of customary closing conditions.

National Securities Corporation, a wholly owned subsidiary of National
Holdings Corporation (NasdaqCM: NHLD), is acting as sole book-running
manager for the offering.

A shelf registration statement relating to the shares of common stock
offered in the underwritten public offering described above was filed
with the Securities and Exchange Commission (“SEC”) on April 3, 2017 and
declared effective by the SEC on April 17, 2017. The offering is being
made only by means of a written prospectus and prospectus supplement
that form a part of the registration statement. A final prospectus
supplement and accompanying prospectus will be filed with the SEC and
will be available on the SEC’s website at www.sec.gov.
Copies of the final prospectus supplement and accompanying prospectus,
when available, may be obtained by contacting the book-running manager
at the following address:

National Securities Corporation
200 Vesey St, 25th Floor
New
York, NY 10281
Attn: Marguerite Rogers
Telephone:
(212)-417-8227
Email: prospectusrequest@nationalsecurities.com

This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of Senseonics, and shall
not constitute an offer, solicitation or sale of any security in any
state or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.

About Senseonics

Senseonics Holdings, Inc. is a medical technology company focused on the
design, development and commercialization of glucose monitoring products
designed to help people with diabetes confidently live their lives with
ease. Senseonics’ first generation continuous glucose monitoring (CGM)
system, Eversense®, includes a small sensor, smart transmitter and
mobile application. Based on fluorescence sensing technology, the sensor
is designed to be inserted subcutaneously and communicate with the smart
transmitter to wirelessly transmit glucose levels to a mobile device.
After insertion, the sensor is designed to continually and accurately
measure glucose levels.

Forward-Looking Statements

Any statements in this press release about future expectations, plans
and prospects for Senseonics, including statements about the closing of
the offering, anticipated use of proceeds and other statements
containing the words “expect,” “intend,” “may,” “will,” and similar
expressions, constitute forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including: the
uncertainties related to market conditions and the completion of the
underwritten public offering on the anticipated terms or at all,
uncertainties inherent in the expanded commercial launch of Eversense
and such other factors as are set forth in the risk factors detailed in
Senseonics’ Annual Report on Form 10-K for the year ended December 31,
2016, Senseonics’ Quarterly Report on Form 10-Q for the quarter ended
June 30, 2017 and Senseonics’ other filings with the SEC under the
heading “Risk Factors.” In addition, the forward-looking statements
included in this press release represent Senseonics’ views as of the
date hereof. Senseonics anticipates that subsequent events and
developments will cause Senseonics’ views to change. However, while
Senseonics may elect to update these forward-looking statements at some
point in the future, Senseonics specifically disclaims any obligation to
do so except as required by law. These forward-looking statements should
not be relied upon as representing Senseonics’ views as of any date
subsequent to the date hereof.

Contacts

Senseonics Holdings, Inc.
R. Don Elsey, 301-556-1602
Chief
Financial Officer

Pruritus Pipeline Report, H2 2017 – Therapeutics Review of 25 Companies & Drug Profiles – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Pruritus
– Pipeline Review, H2 2017”
report has been added to Research
and Markets’
offering.

Pruritus – Pipeline Review, H2 2017, provides comprehensive information
on the therapeutics under development for Pruritus (Dermatology),
complete with analysis by stage of development, drug target, mechanism
of action (MoA), route of administration (RoA) and molecule type. The
guide covers the descriptive pharmacological action of the therapeutics,
its complete research and development history and latest news and press
releases.

The Pruritus (Dermatology) pipeline guide also reviews of key players
involved in therapeutic development for Pruritus and features dormant
and discontinued projects. The guide covers therapeutics under
Development by Companies /Universities /Institutes, the molecules
developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed
and Preclinical stages are 4, 12, 6, 1 and 8 respectively. Similarly,
the Universities portfolio in Preclinical and Discovery stages comprises
3 and 1 molecules, respectively.

Pruritus (Dermatology) pipeline guide helps in identifying and tracking
emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to
gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Pruritus – Overview
  3. Pruritus – Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Pruritus – Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Pruritus – Companies Involved in Therapeutics Development
  • Albireo Pharma Inc
  • Allergan Plc
  • Amorepacific Corp
  • Asana BioSciences LLC
  • Cara Therapeutics Inc
  • Celgene Corp
  • Chugai Pharmaceutical Co Ltd
  • ELORAC Inc
  • GlaxoSmithKline Plc
  • Hydra Biosciences Inc
  • J Uriach Y Compania SA
  • NeuroCycle Therapeutics GmbH
  • Patagonia Pharmaceuticals LLC
  • Patara Pharma Inc
  • Phosphagenics Ltd
  • RDD Pharma Ltd
  • Sanwa Kagaku Kenkyusho Co Ltd
  • Shionogi & Co Ltd
  • Sienna Biopharmaceuticals Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Teikoku Pharma USA Inc
  • Tesaro Inc
  • Tioga Pharmaceuticals Inc
  • Toray Industries Inc
  • Vanda Pharmaceuticals Inc

For more information about this report visit https://www.researchandmarkets.com/research/bfhsp9/pruritus

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Immune
Disorders Drugs

Visceral Pain Pipeline Report, H2 2017 – Therapeutics Review of 10 Companies & Drug Profiles – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Visceral
Pain – Pipeline Review, H2 2017”
report has been added to Research
and Markets’
offering.

Pharmaceutical and Healthcare latest pipeline guide Visceral Pain –
Pipeline Review, H2 2017, provides comprehensive information on the
therapeutics under development for Visceral Pain (Central Nervous
System), complete with analysis by stage of development, drug target,
mechanism of action (MoA), route of administration (RoA) and molecule
type. The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases.

The Visceral Pain (Central Nervous System) pipeline guide also reviews
of key players involved in therapeutic development for Visceral Pain and
features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes,
the molecules developed by Companies in Phase II, IND/CTA Filed and
Preclinical stages are 1, 1 and 11 respectively. Similarly, the
Universities portfolio in Preclinical stages comprises 4 molecules,
respectively.

Visceral Pain (Central Nervous System) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Key Topics Covered:

  1. Introduction
  2. Visceral Pain – Overview
  3. Visceral Pain – Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Visceral Pain – Therapeutics Assessment
  10. Assessment by Target
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Visceral Pain – Companies Involved in Therapeutics Development
  • Addex Therapeutics Ltd
  • Anavex Life Sciences Corp
  • Arena Pharmaceuticals Inc
  • BELLUS Health Inc
  • Cadila Healthcare Ltd
  • Chromocell Corp
  • Eli Lilly and Company
  • Grunenthal GmbH
  • Medestea Research & Production SpA
  • Pfizer Inc

For more information about this report visit https://www.researchandmarkets.com/research/mxz6hk/visceral_pain

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Analgesics

NASH (Non-alcoholic Steatohepatitis) Biomarkers Market to Reach $2 Billion by 2025: Analysis By Type, End-Use & Segment – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “NASH
(Non-alcoholic Steatohepatitis) Biomarkers Market Analysis By Type, By
End-Use (Pharma & CRO Industry, Hospitals, Diagnostic Labs, Academic
Research Institutes), And Segment Forecasts, 2014 – 2025”

report has been added to Research and Markets’ offering.

The global non-alcoholic steatohepatitis (NASH) biomarkers market is
expected to reach USD 2.09 billion by 2025, according to this new report.

Increasing incidence of chronic liver diseases is expected to propel the
demand for NASH biomarkers over the forecast period. The National Health
and Nutrition Examination Survey recently found that approximately 30%
of Nonalcoholic Fatty Liver Diseases (NAFLD) occurred in the U.S. alone.
This disease remains undiagnosed, as a liver can remain fatty without
any change in its function. However, it can progress into a serious
condition, known as nonalcoholic steatosis that may result in liver
failure. NASH is characterized by inflammation and irreversible cell
death.

Rising demand for non-invasive diagnostic tools for detection of NASH is
another driver of market. Traditionally, liver biopsy is performed to
diagnose NAFLD and its degenerative condition, that is, NASH. This
technique is expensive and invasive in nature. This disadvantage has led
to the development of noninvasive and cost-efficient diagnostic
techniques such as biomarker tests. It is observed that many key
companies spent significantly on research and development activities to
introduce novel biomarker tests. These factors are expected to propel
NASH biomarkers market in the coming years.

Companies Mentioned

  • GENFIT SA
  • Gilead Sciences, Inc. (GILD)
  • AstraZeneca
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Allergan Plc
  • Novo Nordisk A/S
  • Boehringer Ingelheim
  • Pfizer Inc

Key Topics Covered:

1 Research Methodology

2. Executive Summary

3. NASH Biomarkers Market Variables, Trends & Scope

4. NASH Biomarkers Market: Type Estimates & Trend Analysis

5. NASH Biomarkers Market: End-use Estimates & Trend Analysis

6. NASH biomarkers Market: Regional Estimates & Trend Analysis, by Type,
and End-use

7. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/96g3qj/nash

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Biomarkers,
Liver
and Kidney Disorders Drugs

Bristol-Myers Squibb and Pfizer to Highlight Commitment to Reducing the Risk of Stroke Caused by Non-Valvular Atrial Fibrillation (NVAF) and Treating Deep Vein Thrombosis/Pulmonary Embolism (DVT/PE) at ESC Congress 2017

Eliquis® (apixaban)
Clinical Data Include Results from a Phase 4 Trial – EMANATE – to be
Featured in Late-Breaking Science Sessions

Analyses from the ACROPOLIS™ Global Real-World Data Program
Provide Insight into the Anticoagulation of a Broad Range of NVAF
Patients at Risk for Stroke

PRINCETON, N.J. & NEW YORK–(BUSINESS WIRE)–$BMY #AFibBristol-Myers
Squibb Company
(NYSE:BMY) and Pfizer
Inc.
(NYSE:PFE) today announced that 15 abstracts have been accepted
for presentation at the ESC Congress 2017, organized by the European
Society of Cardiology, on August 26-30 in Barcelona, Spain.
Investigational data from the EMANATE [Eliquis evaluated
in acute cardioversion coMpared to usuAl treatmeNts
for AnTicoagulation in subjEcts with
non-valvular atrial fibrillation (NVAF)] clinical trial will be
presented during the Late-Breaking Science hot line session and official
ESC press conference. EMANATE is a Phase 4 clinical trial exploring Eliquis®
(apixaban) versus standard of care (parenteral heparin and/or oral
anticoagulation with a vitamin K antagonist) in patients with NVAF
expected to undergo cardioversion to re-establish a regular heart rhythm.

In addition, analyses from ACROPOLIS™ (Apixaban ExperienCe
Through Real-WOrld POpuLatIon Studies)
– the real-world data program which aims to contribute to the growing
body of evidence related to anticoagulation – will be presented at this
year’s ESC Congress. These analyses focus on the use of Eliquis
in routine clinical practice, including in NVAF patient populations
considered at high risk or particularly vulnerable to stroke or major
bleed due to age, risk prediction scores, and other cardiovascular
comorbidities.

“We are proud to share both clinical trial results and real-world data
analyses that continue to support the medical community in the
advancement of patient care and add to the body of evidence for Eliquis
as a treatment for DVT/PE and for reducing the risk of stroke in NVAF
patients,” said Christoph Koenen, M.D., MBA, VP, Development Lead, Eliquis,
Bristol-Myers Squibb. “These data supplement our pivotal trial results,
providing additional insight into how Eliquis performs in
specific clinical settings such as cardioversion and broad patient
populations representing common clinical practice settings.”

“As physicians evaluate options for reducing stroke risk in patients
with non-valvular atrial fibrillation, they often face questions about
the effectiveness and safety of therapies in day-to-day practice,” said
Rory O’Connor, M.D., Chief Medical Officer, Pfizer Innovative Health.
“Real-world data analyses, such as the results shared at this year’s ESC
Congress, allow us to better understand the usage of Eliquis and
other anticoagulants in a variety of settings and alongside clinical
data, and have the potential to help healthcare providers make more
informed decisions about their patient’s care.”

Initial findings from a Bristol-Myers Squibb (BMS)- and Pfizer-
commissioned global policy research project conducted by The Economist
Intelligence Unit (EIU), the research analysis division of The Economist
Group, will also be presented at the ESC Congress. These findings bring
attention to the global disparity of stroke risk reduction policies, and
inadequate detection of risk factors for stroke – including NVAF – in
clinical practice. The full report, which will be released by The EIU on
September 21, is part of the BMS-Pfizer Alliance’s commitment to
collaborating with patient advocacy and research organizations around
the world to uncover barriers to atrial fibrillation screening and
appropriate treatment to reduce the risk of stroke for patients with
NVAF.

  • Data from the EMANATE trial will be presented during various sessions
    on August 28:

    • 09:17 – 09:25 CET – Press Conference – Hot Line: Late-Breaking
      Clinical Trials 2
    • 11:18 – 11:28 CET – Hot Line: Late-Breaking Clinical Trials 2
    • 15:40 – 16:00 CET – Meet the Trialists – EMANATE
    • 15:37 – 18:00 CET – Anticoagulation for cardioversion of atrial
      fibrillation: exploring areas of uncertainty
  • One-year follow-up data evaluating the safety and effectiveness of
    continued oral anticoagulation treatment beyond one year after venous
    thromboembolism (VTE) in patients at intermediate risk of recurrence
    will be presented as an oral presentation on August 26, from 14:24 to
    14:42 CET.
  • A real-world data analysis investigating the safety and effectiveness
    of Eliquis in high-risk patient subgroups will be featured as
    part of the Stroke Prevention poster session on August 28, from
    8:30 to 12:30 CET.
  • A real-world data analysis evaluating the safety and effectiveness of Eliquis
    specifically in NVAF patients aged 65 years and older will be
    presented as an oral presentation during the Anticoagulation in
    Atrial Fibrillation
    Rapid Fire Abstract session on August 29 from
    15:12 to 15:21 CET.
  • Top-line findings from The EIU report on stroke risk reduction and
    screening policies in 12 countries will be presented as a poster on
    August 28, from 8:30 to 12:30 CET. The full report will be released by
    The EIU on September 21.

Below is a complete list of BMS and Pfizer Alliance presentations during
the ESC Congress. Abstracts can be accessed through the ESC
Congress 2017 Scientific Programme
.

             
Title   Presenting Author/Type   Date/Time (CET)   Location/Session
Clinical Data
INR prior to bleeding is below 3.0 most of the time in patients with
atrial fibrillation using warfarin

 

Session: Poster Session 3 – Drug Treatment

  Oliveira Guimaraes et al./ Poster   Aug. 27,

14:00-18:00

  Poster Area
Apixaban vs conventional therapy in anticoagulation-naive patients
with atrial fibrillation undergoing cardioversion: The EMANATE Trial

 

Sessions:

Hot Line: Late-Breaking Clinical Trials 2

Meet the Trialists – EMANATE

  Ezekowitz et al./

Hot Line

Meet the Trialists

  Aug. 28,
Hot Line: 11:18-11:28
Meet the
Trialists:
15:40 – 16:00
  Hot Line:

Main Auditorium

Meet the Trialists:

Dali – The Hub

Serial IL-6 levels and risk of death in anticoagulated patients with
atrial fibrillation: Insights from the ARISTOTLE trial

 

Session: Poster Session 4 – Stroke Prevention

  Aulin et al./

Poster

  Aug. 28,

8:30-12:30

  Poster Area
Clinical outcomes in patients with atrial fibrillation and
echocardiographic risk factors for stroke anticoagulated with
apixaban or warfarin

 

Session: Poster Session 4 – Stroke Prevention

  Vinereanu et al./ Poster   Aug. 28,

8:30-12:30

  Poster Area
Low apolipoprotein A1 is significantly associated with decreased
risk of cardiovascular events in anticoagulated patients with atrial
fibrillation: Insights from the ARISTOTLE trial

 

Session: Poster Session 4 – Atrial Fibrillation Obesity

  Pol et al./

Poster

  Aug. 28,

8:30-12:30

  Poster Area

A novel biomarker-based risk score to predict death in patients
with atrial fibrillation: Insights from the ARISTOTLE and RE-LY
trials

 

Session: Stroke risk prediction in atrial fibrillation

  Hijazi et al./

Poster

  Aug. 29,

14:54-15:12

  Valetta – Village 5
Real-World Data and Other Analyses

Effectiveness and safety of continued oral anticoagulation
treatment beyond 1 year after venous thromboembolism in patients
at intermediate risk: a nationwide propensity score
weighted-cohort study

 

Session: After pulmonary embolism: optimising treatment and
follow up

  Johnsen et al./Oral   Aug. 26,

14:24-14:42

  Rabat – Village 7
Real-world comparison of major bleeding risk associated with direct
oral anticoagulants or warfarin in patients with non-valvular atrial
fibrillation: a systematic review and network meta-analysis

 

Session: Poster Session 3 – Drug Treatment

  Deitelzweig et al./Poster   Aug. 27,

14:00-18:00

  Poster Area

Effectiveness and safety of apixaban versus warfarin among
high-risk subgroups of non-valvular atrial fibrillation patients:
a propensity score matched analysis

 

Session: Poster Session 4 – Stroke Prevention

  Li et al./

Poster

  Aug. 28,

8:30-12:30

  Poster Area

Predictors of warfarin discontinuation or switching among
non-valvular atrial fibrillation patients

 

Session: Poster Session 4 – Stroke Prevention

  Luo et al./

Poster

  Aug. 28,

8:30-12:30

  Poster Area
Effectiveness and safety of standard and lower dose apixaban
compared to warfarin in non-valvular atrial fibrillation patients: a
propensity score matched analysis

 

Session: Poster Session 4 – Stroke Prevention

  Li et al./

Poster

  Aug. 28,

8:30-12:30

  Poster Area
Stroke prevention: From policy to clinical practice in the U.S. and
Europe

 

Session: Poster Session 4 – Cardiovascular risk factors in
general population

 

Karnad et al./Poster

  Aug. 28,

8:30-12:30

  Poster Area
A changing landscape: temporal trends in incidence and
characteristics of patients hospitalised with venous thromboembolism.

 

Session: Best Posters – Best Posters in acute pulmonary
embolism

  Johnsen et al./Poster   Aug. 28, 14:00-18:00   Poster Area

Risk of major bleeding among non-valvular atrial fibrillation
patients prescribed apixaban, dabigatran, rivaroxaban or warfarin
in the U.S. Medicare population

 

Session: Poster Session 5 – Bleeding and LAA Occlusion

  Trocio et al./

Poster

  Aug. 28,

14:00-18:00

  Poster Area

Comparison of stroke and major bleeding risk of treatment with
apixaban vs. rivaroxaban and dabigatran among elderly non-valvular
atrial fibrillation patients in the United States

 

Session: Anticoagulation in Atrial Fibrillation

  Deitelzweig et al./Rapid Fire Abstract   Aug. 29,

15:12-15:21

  Agora 2
     

About Eliquis

Eliquis (apixaban) is an oral selective Factor Xa inhibitor. By
inhibiting Factor Xa, a key blood clotting protein, Eliquis
decreases thrombin generation and blood clot formation. Eliquis is
approved for multiple indications in the U.S. based on efficacy and
safety data from multiple Phase 3 clinical trials. Eliquis is a
prescription medicine indicated to reduce the risk of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation
(NVAF); for the prophylaxis of deep vein thrombosis (DVT), which may
lead to pulmonary embolism (PE), in patients who have undergone hip or
knee replacement surgery; for the treatment of DVT and PE; and to reduce
the risk of recurrent DVT and PE, following initial therapy.

ELIQUIS Important Safety Information

 
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE
RISK OF THROMBOTIC EVENTS, (B) SPINAL/EPIDURAL HEMATOMA
 
(A) Premature discontinuation of any oral anticoagulant,
including ELIQUIS, increases the risk of thrombotic events. If
anticoagulation with ELIQUIS is discontinued for a reason other than
pathological bleeding or completion of a course of therapy, consider
coverage with another anticoagulant.
 

(B) Epidural or spinal hematomas may occur in patients treated
with ELIQUIS who are receiving neuraxial anesthesia or undergoing
spinal puncture. These hematomas may result in long-term or
permanent paralysis. Consider these risks when scheduling patients
for spinal procedures. Factors that can increase the risk of
developing epidural or spinal hematomas in these patients include:

 

• use of indwelling epidural catheters

• concomitant use of other drugs that affect hemostasis, such
as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet
inhibitors, other anticoagulants

• a history of traumatic or repeated epidural or spinal
punctures

• a history of spinal deformity or spinal surgery

• optimal timing between the administration of ELIQUIS and
neuraxial procedures is not known

 
Monitor patients frequently for signs and symptoms of
neurological impairment. If neurological compromise is noted, urgent
treatment is necessary.
 
Consider the benefits and risks before neuraxial intervention in
patients anticoagulated or to be anticoagulated.
 

CONTRAINDICATIONS

  • Active pathological bleeding
  • Severe hypersensitivity reaction to ELIQUIS (e.g., anaphylactic
    reactions)

WARNINGS AND PRECAUTIONS

  • Increased Risk of Thrombotic Events after Premature
    Discontinuation:
    Premature discontinuation of any oral
    anticoagulant, including ELIQUIS, in the absence of adequate
    alternative anticoagulation increases the risk of thrombotic events.
    An increased rate of stroke was observed during the transition from
    ELIQUIS to warfarin in clinical trials in atrial fibrillation
    patients. If ELIQUIS is discontinued for a reason other than
    pathological bleeding or completion of a course of therapy, consider
    coverage with another anticoagulant.
  • Bleeding Risk: ELIQUIS increases the risk of bleeding and can
    cause serious, potentially fatal, bleeding.

    • Concomitant use of drugs affecting hemostasis increases the risk
      of bleeding, including aspirin and other antiplatelet agents,
      other anticoagulants, heparin, thrombolytic agents, SSRIs, SNRIs,
      and NSAIDs.
    • Advise patients of signs and symptoms of blood loss and to report
      them immediately or go to an emergency room. Discontinue ELIQUIS
      in patients with active pathological hemorrhage.
    • There is no established way to reverse the anticoagulant effect of
      apixaban, which can be expected to persist for at least 24 hours
      after the last dose (i.e., about two half-lives). A specific
      antidote for ELIQUIS is not available.
  • Spinal/Epidural Anesthesia or Puncture: Patients treated with
    ELIQUIS undergoing spinal/epidural anesthesia or puncture may develop
    an epidural or spinal hematoma which can result in long-term or
    permanent paralysis.

    The risk of these events may be
    increased by the postoperative use of indwelling epidural catheters or
    the concomitant use of medicinal products affecting hemostasis.
    Indwelling epidural or intrathecal catheters should not be removed
    earlier than 24 hours after the last administration of ELIQUIS. The
    next dose of ELIQUIS should not be administered earlier than 5 hours
    after the removal of the catheter. The risk may also be increased by
    traumatic or repeated epidural or spinal puncture. If traumatic
    puncture occurs, delay the administration of ELIQUIS for 48 hours.

    Monitor
    patients frequently and if neurological compromise is noted, urgent
    diagnosis and treatment is necessary. Physicians should consider the
    potential benefit versus the risk of neuraxial intervention in ELIQUIS
    patients.

  • Prosthetic Heart Valves: The safety and efficacy of ELIQUIS
    have not been studied in patients with prosthetic heart valves and is
    not recommended in these patients.
  • Acute PE in Hemodynamically Unstable Patients or Patients who
    Require Thrombolysis or Pulmonary Embolectomy:
    Initiation of
    ELIQUIS is not recommended as an alternative to unfractionated heparin
    for the initial treatment of patients with PE who present with
    hemodynamic instability or who may receive thrombolysis or pulmonary
    embolectomy.

ADVERSE REACTIONS

  • The most common and most serious adverse reactions reported with
    ELIQUIS were related to bleeding.

TEMPORARY INTERRUPTION FOR SURGERY AND OTHER INTERVENTIONS

  • ELIQUIS should be discontinued at least 48 hours prior to elective
    surgery or invasive procedures with a moderate or high risk of
    unacceptable or clinically significant bleeding. ELIQUIS should be
    discontinued at least 24 hours prior to elective surgery or invasive
    procedures with a low risk of bleeding or where the bleeding would be
    noncritical in location and easily controlled. Bridging
    anticoagulation during the 24 to 48 hours after stopping ELIQUIS and
    prior to the intervention is not generally required. ELIQUIS should be
    restarted after the surgical or other procedures as soon as adequate
    hemostasis has been established.

DRUG INTERACTIONS

  • Strong Dual Inhibitors of CYP3A4 and P-gp: Inhibitors of
    cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp) increase
    exposure to apixaban and increase the risk of bleeding. For patients
    receiving ELIQUIS doses of 5 mg or 10 mg twice daily, reduce the dose
    of ELIQUIS by 50% when ELIQUIS is coadministered with drugs that are
    strong dual inhibitors of CYP3A4 and P-gp (e.g., ketoconazole,
    itraconazole, ritonavir, or clarithromycin). In patients already
    taking 2.5 mg twice daily, avoid coadministration of ELIQUIS with
    strong dual inhibitors of CYP3A4 and P-gp.
  • Strong Dual Inducers of CYP3A4 and P-gp: Avoid concomitant use
    of ELIQUIS with strong dual inducers of CYP3A4 and P-gp (e.g.,
    rifampin, carbamazepine, phenytoin, St. John’s wort) because such
    drugs will decrease exposure to apixaban and increase the risk of
    stroke and other thromboembolic events.
  • Anticoagulants and Antiplatelet Agents: Coadministration of
    antiplatelet agents, fibrinolytics, heparin, aspirin, and chronic
    NSAID use increases the risk of bleeding. APPRAISE-2, a
    placebo-controlled clinical trial of apixaban in high-risk post-acute
    coronary syndrome patients treated with aspirin or the combination of
    aspirin and clopidogrel, was terminated early due to a higher rate of
    bleeding with apixaban compared to placebo.

PREGNANCY CATEGORY B

  • There are no adequate and well-controlled studies of ELIQUIS in
    pregnant women. Treatment is likely to increase the risk of hemorrhage
    during pregnancy and delivery. ELIQUIS should be used during pregnancy
    only if the potential benefit outweighs the potential risk to the
    mother and fetus.

Please see full Prescribing Information, including BOXED WARNINGS and
Medication Guide, available at
www.bms.com.

About ACROPOLIS™

ACROPOLIS™(Apixaban ExperienCe Through Real-WOrld
POpuLatIon Studies) is the Eliquis
(apixaban) global real-world data program designed to generate
additional evidence from routine clinical practice settings to further
inform healthcare decision makers, including healthcare providers and
payers. The ACROPOLIS program will include retrospective, outcomes-based
analyses from over 10 databases around the world, including medical
records, medical and pharmacy health insurance claims data, and national
health data systems.

Analyses of real-world data allow for a broader understanding of patient
outcomes associated with Eliquis outside of the clinical trial
setting, as well as insight into other measures of healthcare delivery,
such as hospitalization and costs.

About ARISTOTLE

ARISTOTLE (Apixaban for Reduction In STroke
and Other ThromboemboLic Events in Atrial
Fibrillation) was designed to evaluate the efficacy and safety of Eliquis
versus warfarin for the prevention of stroke or systemic embolism. In
ARISTOTLE, 18,201 patients were randomized (9,120 patients to Eliquis
and 9,081 to warfarin). ARISTOTLE was an active-controlled, randomized,
double-blind, multi-national trial in patients with nonvalvular atrial
fibrillation or atrial flutter, and at least one additional risk factor
for stroke. Patients were randomized to treatment with Eliquis 5
mg orally twice daily (or 2.5 mg twice daily in selected patients,
representing 4.7 percent of all patients) or warfarin (target INR range
2.0-3.0), and followed for a median of 1.8 years.

About the Bristol-Myers Squibb/Pfizer Collaboration

In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide
collaboration to develop and commercialize apixaban, an oral
anticoagulant discovered by Bristol-Myers Squibb. This global alliance
combines Bristol-Myers Squibb’s long-standing strengths in
cardiovascular drug development and commercialization with Pfizer’s
global scale and expertise in this field.

About Bristol-Myers Squibb

Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit us at BMS.com
or follow us on LinkedIn,
Twitter,
YouTube
and Facebook.

About Pfizer Inc.: Working together for a healthier world®

At Pfizer, we apply science and our global resources to bring therapies
to people that extend and significantly improve their lives. We strive
to set the standard for quality, safety and value in the discovery,
development and manufacture of health care products. Our global
portfolio includes medicines and vaccines as well as many of the world’s
best-known consumer health care products. Every day, Pfizer colleagues
work across developed and emerging markets to advance wellness,
prevention, treatments and cures that challenge the most feared diseases
of our time. Consistent with our responsibility as one of the world’s
premier innovative biopharmaceutical companies, we collaborate with
health care providers, governments and local communities to support and
expand access to reliable, affordable health care around the world. For
more than 150 years, we have worked to make a difference for all who
rely on us. We routinely post information that may be important to
investors on our website at www.pfizer.com.
In addition, to learn more, please visit us on www.pfizer.com
and follow us on Twitter at @Pfizer
and @PfizerNews,
LinkedIn,
YouTube
and like us on Facebook at Facebook.com/Pfizer.

Bristol-Myers Squibb Forward-Looking Statement

This press release contains “forward-looking statements” as that term
is defined in the Private Securities Litigation Reform Act of 1995
regarding product development. Such forward-looking statements are based
on current expectations and involve inherent risks and uncertainties,
including factors that could delay, divert or change any of them, and
could cause actual outcomes and results to differ materially from
current expectations. No forward-looking statement can be guaranteed.
Forward-looking statements in this press release should be evaluated
together with the many uncertainties that affect Bristol-Myers Squibb’s
business, particularly those identified in the cautionary factors
discussion in Bristol-Myers Squibb’s Annual Report on Form 10-K for the
year ended December 31, 2016, in our Quarterly Reports on Form 10-Q and
our Current Reports on Form 8-K. Bristol-Myers Squibb undertakes no
obligation to publicly update any forward-looking statement, whether as
a result of new information, future events or otherwise.

Pfizer Disclosure Notice

The information contained in this release is as of August 18, 2017.
Pfizer assumes no obligation to update forward-looking statements
contained in this release as the result of new information or future
events or developments.

This release contains forward-looking information about Eliquis
(apixaban), including its potential benefits, that involves substantial
risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. Risks and
uncertainties include, among other things, the uncertainties inherent in
research and development, including, without limitation, the ability to
meet anticipated clinical trial commencement and completion dates as
well as the possibility of unfavorable clinical trial results, including
unfavorable new clinical data and additional analyses of existing
clinical data; decisions by regulatory authorities regarding labeling
and other matters that could affect the availability or commercial
potential of Eliquis; and competitive developments.

A further description of risks and uncertainties can be found in
Pfizer’s Annual Report on Form 10-K for the fiscal year ended December
31, 2016 and in its subsequent reports on Form 10-Q, including in the
sections thereof captioned “Risk Factors” and “Forward-Looking
Information and Factors That May Affect Future Results”, as well as in
its subsequent reports on Form 8-K, all of which are filed with the SEC
and available at
www.sec.gov
and
www.pfizer.com.

Contacts

Bristol-Myers Squibb
Media:
Rob Perry, 407-492-4616
rob.perry@bms.com
or
Investors:
Timothy
Power, 609-252-7509
timothy.power@bms.com
or
Pfizer
Inc.
Media:
Steven Danehy, 212-733-1538
steven.danehy@pfizer.com
or
Investors:
Ryan
Crowe, 212-733-8160
ryan.crowe@pfizer.com

Biopharmaceutical CMO & CRO Market (2017-2025) – Analysis By Source, Service Type, Product & Segment – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Biopharmaceutical
CMO & CRO Market Analysis By Source (Mammalian, Non-mammalian), By
Service Type (Contract Manufacturing, Contract Research), By Product,
And Segment Forecasts, 2014 – 2025”
report has been added to Research
and Markets’
offering.

The global biopharmaceutical CMO & CRO (contract manufacturing &
research) market is expected to reach USD 37.8 billion by 2025,
according to this new report.

Healthy outlook of biopharmaceuticals and consequent growth in
biopharmaceutical pipelines has resulted into lack of adequate capacity
and budget constraints. These factors have convinced many traditional
drug developers to take advantage of cost-saving benefits associated
with contract services. Traditional biopharmaceutical players are
observed to choose outsourcing biopharmaceutical manufacturing rather
than making an investment of expensive capital in production equipment
and hiring skilled labor.

Significant improvement in the services offered by this CMOs/CROs in
context to maturity of complex technology is spurring the adoption of
these services. In addition, wide acceptance of single-use technology
within CMOs/CROs has significantly transformed the CMOs/CROs landscape
by enhancing their capabilities and enabling them to develop products at
low operating costs.

Outsourcing services are observed to play critical role in overcoming
trade barriers for firms. It enables them to make footprints in foreign
market where government regulates to secure local employment through
domestic production. Furthermore, as a result of growing demand for
these services, smaller companies have also begun to expand their
non-GMP facilities.

Companies Mentioned

  • Boehringer Ingelheim GmbH
  • LONZA
  • Inno Biologics Sdn Bhd
  • Rentschler Biotechnologie GmbH
  • JRS PHARMA
  • CELONIC AG
  • BIOMEVA GmbH
  • ProBioGen
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • TOYOBO CO., LTD.
  • Samsung BioLogics
  • Patheon
  • DPx
  • CMC Biologics
  • Binex Co., Ltd.
  • WuXi Biologics
  • AbbVie, Inc.

Key Topics Covered:

1. Research Methodology

2. Executive Summary

3. Market Variables, Trends & Scope

4. Biopharmaceuticals CMO & CRO Market: Source Estimates & Trend Analysis

5. Biopharmaceuticals CMO & CRO Market: Service Type Estimates & Trend
Analysis

6. Biopharmaceuticals CMO & CRO Market: Product Estimates & Trend
Analysis

7. Biopharmaceuticals CMO & CRO Market: Regional Estimates & Trend
Analysis, by Service, Source, & Product

8. Competitive Landscape

For more information about this report visit https://www.researchandmarkets.com/research/mwb4sd/biopharmaceutical

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Drug
Discovery
, Biopharmaceuticals

Global Urinary Tract Infection Treatment Market to Grow at a CAGR of 2.1% by 2021: Key Vendors are Merck, Bayer, Johnson & Johnson, and Novartis – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Global
Urinary Tract Infection Treatment Market 2017-2021”
report has
been added to Research and Markets’ offering.

The global urinary tract infection treatment market to grow at a CAGR of
2.15% during the period 2017-2021.

The report, Global Urinary Tract Infection Treatment Market 2017-2021,
has been prepared based on an in-depth market analysis with inputs from
industry experts. The report covers the market landscape and its growth
prospects over the coming years. The report also includes a discussion
of the key vendors operating in this market.

The latest trend gaining momentum in the market is growing awareness of
controlled usage of antibiotics. Antibiotic resistance is one of the
major problem being faced by the medical world today. Antibiotic
resistance can be defined as a term when a microorganism changes itself
and remains no longer sensitive to that particular antibiotic. In this
condition, the antibiotic is no longer capable of killing or inhibiting
the growth of the bacteria.

According to the report, one of the major drivers for this market is the
relation of UTI with several other factors leading to rising incidence
rate of UTI. Interconnection of UTI with other healthcare conditions and
changing lifestyle habits have led to the rising incidence of the
disease. This, in turn, is expected to rise the demand for the treatment
facilities for the UTI. The disease is more common in women as compared
with men. Around 50% of the women globally have chances of developing
UTI at least once in their lifetime. This accounts for a large
population and demands huge attention. Apart from gender, many other
factors such as obesity and diabetes contribute to the rising incidence
of UTI.

Key vendors

  • Merck,
  • Bayer,
  • Johnson & Johnson,
  • Novartis

Other prominent vendors

  • Achaogen
  • Allergan
  • Aquinox Pharmaceuticals
  • AstraZeneca
  • Others

Key Topics Covered:

PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

PART 05: Market landscape

PART 06: Pipeline analysis

PART 07: Market segmentation by disease type

PART 08: Geographical segmentation

PART 09: Decision framework

PART 10: Drivers and challenges

PART 11: Market trends

PART 12: Vendor landscape

PART 13: Key vendor analysis

PART 14: Appendix

For more information about this report visit https://www.researchandmarkets.com/research/knhwps/global_urinary

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Infectious
Diseases Drugs
, Urological
Disorders Drugs

World Inulin (CAS 9005-80-5) Market Research Report 2017 – Research and Markets

DUBLIN–(BUSINESS WIRE)–The “Inulin
(CAS 9005-80-5) Market Research Report 2017”
report has been
added to Research and Markets’ offering.

This Global Report 2017 is a result of industry experts’ diligent work
on researching the world market of Inulin. The report helps to build up
a clear view of the market (trends and prospects), identify major
players in the industry, and estimate main downstream sectors.

The first chapter introduces the product by providing review of the most
of its characteristics (composition, structure, hazards, storage,
toxicological & ecological information, etc.).

The second chapter focuses on Inulin end-uses, the third one gives
summary on a number of patents.

The fourth chapter deals with Inulin market trends review, distinguish
Inulin manufacturers and suppliers.

The chapter 5 summarizes Inulin prices data.

The last chapter analyses Inulin downstream markets.

The Inulin global market report 2017 key points:

– Inulin description, its application areas and related patterns

– Inulin market situation

– Inulin manufacturers and distributors

– Inulin prices (by region and provided by market players)

– Inulin end-uses breakdown

– Inulin downstream industries trends

Key Topics Covered:

1. INULIN GENERAL INFORMATION

1.1. General information, synonyms

1.2. Composition, chemical structure

1.3. Safety information

1.4. Hazards identification

1.5. Handling and storage

1.6. Toxicological & ecological information

2. INULIN APPLICATION

3. INULIN MANUFACTURING METHODS

4. INULIN PATENTS

5. INULIN MARKET WORLDWIDE

5.1. General Inulin market situation, trends

5.2. Manufacturers of Inulin

5.3. Suppliers of Inulin

5.4. Praduct market forecast

6. INULIN MARKET PRICES

7. INULIN END-USE SECTOR

For more information about this report visit https://www.researchandmarkets.com/research/r94n7b/inulin_cas

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S.
Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related
Topics: Vitamins
and Dietary Supplements